- Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies STAT
- Patient Dies After Receiving Sarepta’s Gene Therapy Barron’s
- Gene-Therapy Maker Sarepta Tanks After Patient Death The Wall Street Journal
- Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying. MarketWatch
- Sarepta Shares Fall on Report of Patient Death After Gene Therapy Bloomberg
Powered by WPeMatico